EQT Public Value Invests in BioGaia AB

EQT Public Value Takes 2.7% Stake in Securitas AB

September 11, 2020

Professional Services

EQT Public Value, advised by EQT Partners, has acquired 10 million shares in Securitas AB, representing a 2.7% ownership and making it the company's fourth-largest shareholder. The minority investment is intended to support Securitas' ongoing transformation by providing active shareholder engagement and access to EQT's platform capabilities, including digital and sustainability expertise.

EQT Public Value Takes ~10% Stake in Storytel AB

September 7, 2021

Media & Entertainment

EQT Public Value acquired 6.6 million shares in Storytel AB, representing close to a 10% ownership stake, and has nominated Joakim Rubin to join Storytel's board subject to an extraordinary general meeting. The minority investment is intended for shareholder engagement to support Storytel's next phase of growth in the audiobook and e-book streaming market.

EQT Growth Invests €100M in IntegrityNext

March 23, 2023

Cloud & SaaS

EQT Growth has made a €100 million growth investment in IntegrityNext, a Munich-based cloud SaaS platform for supply chain sustainability and ESG compliance. The capital will support product expansion to meet upcoming European ESG regulations and accelerate IntegrityNext’s international growth; the company will continue to be led by its co-founders.

Equillium Acquires Bioniz Therapeutics

February 16, 2022

Biotechnology

Equillium, Inc. (Nasdaq: EQ) acquired privately held Bioniz Therapeutics, obtaining exclusive worldwide rights to Bioniz's pipeline (BNZ-1, BNZ-2, BNZ-3) and proprietary discovery platform in an all-stock transaction (5,699,492 shares, ~19.3% of Equillium outstanding) plus up to $57.5M in development milestones and up to $250M in sales milestones. The acquisition expands Equillium's immunology capabilities and pipeline, adding complementary clinical-stage cytokine-targeting assets and key research and clinical personnel.

EQT Acquires Mabtech from IK Partners and Mérieux Equity Partners

January 9, 2024

Biotechnology

EQT, via its newly launched EQT Healthcare Growth Strategy, is acquiring Swedish immunoassay specialist Mabtech AB from IK Partners and Mérieux Equity Partners. Mabtech, a developer and manufacturer of antibodies, kits and readers used in vaccine, infectious disease and oncology research, will be supported by EQT to expand its product portfolio and accelerate geographic growth, particularly in the US. The transaction is subject to customary regulatory approvals and financial terms were not disclosed.

EQT Growth and EQT Ventures Invest in Wolt as Part of $530M Capital Raise

January 25, 2021

Restaurants & Hospitality

EQT Growth has made its first investment by participating in Wolt Enterprises Oy's $530 million capital raise, joining existing investor EQT Ventures. The capital injection will support Wolt's continued international expansion into new geographies and verticals; Wolt is a Helsinki-based food delivery platform operating across 23 countries.